Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Exelixis, Inc.
EXEL
NASDAQ·Healthcare·Biotechnology·Mkt cap $13.6B
$55.01
▲ +1.94%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$33.76 - $56.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 21.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced molecular targeting technologies
- Diverse oncology research pipeline
- Strategic pharmaceutical collaborations
- Proven track record of drug development
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Moderate growth ahead
Expanding oncology treatment market
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Hot
+23.0% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EXEL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 12, 2026
MAY 5, 2026
Reported EPS of $0.87 vs $0.75 consensus (+16.0% surprise). Revenue of $610.8M vs $607.5M expected (+0.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+16.0%
Next: May 12, 2026
Revenue trend · last 8Q
—
—
+18%
+31%
-11%
+11%
+6%
+10%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 26
Q1 26
$637.2M
$539.5M
$566.8M
$555.4M
$568.3M
$597.8M
$598.7M
$610.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
34.5%
Wall Street consensus
8 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
75%
Sell
0%
Median Price Target
$45.00
▼ -18.2% vs $55.01
Latest: UBS · Jul 2, 2026
1 analyst covering